Direct thrombin inhibitors for non-ST–segment elevation acute coronary syndromes: what, when, and where? - 28/08/11
Abstract |
Background |
Unfractionated heparin has been the cornerstone of antithrombin therapy in the treatment of non-ST–segment elevation acute coronary syndromes for more than a decade. Several new anticoagulants have emerged in recent years and have been studied extensively in patients with unstable coronary syndromes and in the percutaneous coronary intervention setting.
Methods |
Direct thrombin inhibitors comprise a family of agents with promising properties that offer several potential advantages over unfractionated heparin. Hirudin has been studied in patients with ST-elevation myocardial infarction, non-ST–elevation coronary syndromes, and coronary angioplasty. Bivalirudin has been studied in patients undergoing percutaneous coronary revascularization, with very promising efficacy and safety profile compared with unfractionated heparin.
Results |
The clinical trials of direct thrombin inhibitors in non-ST–elevation acute coronary syndromes and coronary angioplasty are reviewed.
Le texte complet de cet article est disponible en PDF.Plan
Vol 146 - N° 4S
P. S23-S30 - octobre 2003 Retour au numéro
Article précédent
- Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST–segment elevation myocardial infarction: Appropriate interpretation of the guidelines
- Elliott M Antman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?